Amanote Research
Register
Sign In
Correction: Article on the Characterization and Multiparameter Analysis of Visual Adverse Events in Irofulven Single-Agent Phase I and II Trials
Clinical Cancer Research
- United States
doi 10.1158/1078-0432.ccr-114cor-a
Full Text
Open PDF
Abstract
Available in
full text
Categories
Cancer Research
Oncology
Date
February 15, 2005
Authors
Unknown
Publisher
American Association for Cancer Research (AACR)
Related search
Delayed Adverse Events in Phase I Trials of Molecularly Targeted and Cytotoxic Agents
Oncotarget
Oncology
Prognostic and Predictive Factors Associated With Ipilimumab-Related Adverse Events: A Retrospective Analysis of 11 NCI-sponsored Phase I Clinical Trials
Oncotarget
Oncology
Lipoprotein(a) Reductions From PCSK9 Inhibition and Major Adverse Cardiovascular Events: Pooled Analysis of Alirocumab Phase 3 Trials
Atherosclerosis
Cardiovascular Medicine
Cardiology
Correction To: Serious Adverse Events and Fatal Adverse Events Associated With Nivolumab Treatment in Cancer Patients
Journal for ImmunoTherapy of Cancer
Oncology
Molecular Medicine
Pharmacology
Cancer Research
Allergy
Immunology
FRI0618 Adalimumab in Non-Infectious Uveitis – Efficacy Across Different Etiologies in the Visual I and Visual Ii Trials
Inappropriate Grading of Adverse Events in Cancer Clinical Trials—Reply
JAMA Oncology
Cancer Research
Oncology
Effects of Steroids on Quality of Recovery and Adverse Events After General Anesthesia: Meta-Analysis and Trial Sequential Analysis of Randomized Clinical Trials
PLoS ONE
Multidisciplinary
Long-Term Analysis of Phase II Studies of Single-Agent Lenalidomide in Relapsed/Refractory Mantle Cell Lymphoma
American Journal of Hematology
Hematology
Failure to Report Harms and Adverse Events in Clinical Trials: Why Does the Problem Continue?
Canadian Journal of Anaesthesia
Medicine
Anesthesiology
Pain Medicine
